Page last updated: 2024-08-16

thalidomide and cpi203

thalidomide has been researched along with cpi203 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bladé, J; Calderón, M; de Larrea, CF; Díaz, T; Lozano, E; Martínez, A; Mena, MP; Pérez-Galán, P; Rodríguez, V; Rosiñol, L; Roué, G; Tovar, N	1

Other Studies

1 other study(ies) available for thalidomide and cpi203

Article	Year
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in Haematologica, 2017, Volume: 102, Issue:10 Topics: Acetamides; Aged; Aged, 80 and over; Animals; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Disease Models, Animal; Drug Synergism; Female; Gene Expression Profiling; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Mice; Middle Aged; Multiple Myeloma; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays	2017

Article

Year

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in

Haematologica, 2017, Volume: 102, Issue:10

Topics: Acetamides; Aged; Aged, 80 and over; Animals; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Disease Models, Animal; Drug Synergism; Female; Gene Expression Profiling; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Mice; Middle Aged; Multiple Myeloma; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays

2017